The global Galectin Inhibitor Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Galectin Inhibitor Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Galectin Inhibitor Therapeutics.

Report Scope

The Galectin Inhibitor Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (Kiloton) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Galectin Inhibitor Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Galectin Inhibitor Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Galectin Inhibitor Therapeutics Market Report

Report Metric	Details
Report Name	Galectin Inhibitor Therapeutics Market
CAGR	5%
Segment by Type	Natural Synthetic
Segment by Application	Diabetes Heart Failure Asthma Rheumatoid Arthritis Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	GlycoMimetics (US), Galectin Therapeutics Inc (US), G3 Pharmaceuticals (India), iTeos (US), MandalMed, Inc (US), Angion (US), Novartis AG (Switzerland), Galecto Biotech (Denmark), Pfizer Inc. (US), Lilly (US)
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Galectin Inhibitor Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Galectin Inhibitor Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Galectin Inhibitor Therapeutics Market report?

Ans: The main players in the Galectin Inhibitor Therapeutics Market are GlycoMimetics (US), Galectin Therapeutics Inc (US), G3 Pharmaceuticals (India), iTeos (US), MandalMed, Inc (US), Angion (US), Novartis AG (Switzerland), Galecto Biotech (Denmark), Pfizer Inc. (US), Lilly (US)

What are the Application segmentation covered in the Galectin Inhibitor Therapeutics Market report?

Ans: The Applications covered in the Galectin Inhibitor Therapeutics Market report are Diabetes, Heart Failure, Asthma, Rheumatoid Arthritis, Other

What are the Type segmentation covered in the Galectin Inhibitor Therapeutics Market report?

Ans: The Types covered in the Galectin Inhibitor Therapeutics Market report are Natural, Synthetic

1 Galectin Inhibitor Therapeutics Market Overview

1.1 Product Overview and Scope of Galectin Inhibitor Therapeutics

1.2 Galectin Inhibitor Therapeutics Segment by Type

1.2.1 Global Galectin Inhibitor Therapeutics Market Value Comparison by Type (2024-2030)

1.2.2 Natural

1.2.3 Synthetic

1.3 Galectin Inhibitor Therapeutics Segment by Application

1.3.1 Global Galectin Inhibitor Therapeutics Market Value by Application: (2024-2030)

1.3.2 Diabetes

1.3.3 Heart Failure

1.3.4 Asthma

1.3.5 Rheumatoid Arthritis

1.3.6 Other

1.4 Global Galectin Inhibitor Therapeutics Market Size Estimates and Forecasts

1.4.1 Global Galectin Inhibitor Therapeutics Revenue 2019-2030

1.4.2 Global Galectin Inhibitor Therapeutics Sales 2019-2030

1.4.3 Global Galectin Inhibitor Therapeutics Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Galectin Inhibitor Therapeutics Market Competition by Manufacturers

2.1 Global Galectin Inhibitor Therapeutics Sales Market Share by Manufacturers (2019-2024)

2.2 Global Galectin Inhibitor Therapeutics Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Galectin Inhibitor Therapeutics Average Price by Manufacturers (2019-2024)

2.4 Global Galectin Inhibitor Therapeutics Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Galectin Inhibitor Therapeutics, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Galectin Inhibitor Therapeutics, Product Type & Application

2.7 Galectin Inhibitor Therapeutics Market Competitive Situation and Trends

2.7.1 Galectin Inhibitor Therapeutics Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Galectin Inhibitor Therapeutics Players Market Share by Revenue

2.7.3 Global Galectin Inhibitor Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Galectin Inhibitor Therapeutics Retrospective Market Scenario by Region

3.1 Global Galectin Inhibitor Therapeutics Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Galectin Inhibitor Therapeutics Global Galectin Inhibitor Therapeutics Sales by Region: 2019-2030

3.2.1 Global Galectin Inhibitor Therapeutics Sales by Region: 2019-2024

3.2.2 Global Galectin Inhibitor Therapeutics Sales by Region: 2025-2030

3.3 Global Galectin Inhibitor Therapeutics Global Galectin Inhibitor Therapeutics Revenue by Region: 2019-2030

3.3.1 Global Galectin Inhibitor Therapeutics Revenue by Region: 2019-2024

3.3.2 Global Galectin Inhibitor Therapeutics Revenue by Region: 2025-2030

3.4 North America Galectin Inhibitor Therapeutics Market Facts & Figures by Country

3.4.1 North America Galectin Inhibitor Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Galectin Inhibitor Therapeutics Sales by Country (2019-2030)

3.4.3 North America Galectin Inhibitor Therapeutics Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Galectin Inhibitor Therapeutics Market Facts & Figures by Country

3.5.1 Europe Galectin Inhibitor Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Galectin Inhibitor Therapeutics Sales by Country (2019-2030)

3.5.3 Europe Galectin Inhibitor Therapeutics Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Galectin Inhibitor Therapeutics Market Facts & Figures by Country

3.6.1 Asia Pacific Galectin Inhibitor Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Galectin Inhibitor Therapeutics Sales by Country (2019-2030)

3.6.3 Asia Pacific Galectin Inhibitor Therapeutics Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Galectin Inhibitor Therapeutics Market Facts & Figures by Country

3.7.1 Latin America Galectin Inhibitor Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Galectin Inhibitor Therapeutics Sales by Country (2019-2030)

3.7.3 Latin America Galectin Inhibitor Therapeutics Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Galectin Inhibitor Therapeutics Market Facts & Figures by Country

3.8.1 Middle East and Africa Galectin Inhibitor Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Galectin Inhibitor Therapeutics Sales by Country (2019-2030)

3.8.3 Middle East and Africa Galectin Inhibitor Therapeutics Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Galectin Inhibitor Therapeutics Sales by Type (2019-2030)

4.1.1 Global Galectin Inhibitor Therapeutics Sales by Type (2019-2024)

4.1.2 Global Galectin Inhibitor Therapeutics Sales by Type (2025-2030)

4.1.3 Global Galectin Inhibitor Therapeutics Sales Market Share by Type (2019-2030)

4.2 Global Galectin Inhibitor Therapeutics Revenue by Type (2019-2030)

4.2.1 Global Galectin Inhibitor Therapeutics Revenue by Type (2019-2024)

4.2.2 Global Galectin Inhibitor Therapeutics Revenue by Type (2025-2030)

4.2.3 Global Galectin Inhibitor Therapeutics Revenue Market Share by Type (2019-2030)

4.3 Global Galectin Inhibitor Therapeutics Price by Type (2019-2030)

5 Segment by Application

5.1 Global Galectin Inhibitor Therapeutics Sales by Application (2019-2030)

5.1.1 Global Galectin Inhibitor Therapeutics Sales by Application (2019-2024)

5.1.2 Global Galectin Inhibitor Therapeutics Sales by Application (2025-2030)

5.1.3 Global Galectin Inhibitor Therapeutics Sales Market Share by Application (2019-2030)

5.2 Global Galectin Inhibitor Therapeutics Revenue by Application (2019-2030)

5.2.1 Global Galectin Inhibitor Therapeutics Revenue by Application (2019-2024)

5.2.2 Global Galectin Inhibitor Therapeutics Revenue by Application (2025-2030)

5.2.3 Global Galectin Inhibitor Therapeutics Revenue Market Share by Application (2019-2030)

5.3 Global Galectin Inhibitor Therapeutics Price by Application (2019-2030)

6 Key Companies Profiled

6.1 GlycoMimetics (US)

6.1.1 GlycoMimetics (US) Corporation Information

6.1.2 GlycoMimetics (US) Description and Business Overview

6.1.3 GlycoMimetics (US) Galectin Inhibitor Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.1.4 GlycoMimetics (US) Galectin Inhibitor Therapeutics Product Portfolio

6.1.5 GlycoMimetics (US) Recent Developments/Updates

6.2 Galectin Therapeutics Inc (US)

6.2.1 Galectin Therapeutics Inc (US) Corporation Information

6.2.2 Galectin Therapeutics Inc (US) Description and Business Overview

6.2.3 Galectin Therapeutics Inc (US) Galectin Inhibitor Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Galectin Therapeutics Inc (US) Galectin Inhibitor Therapeutics Product Portfolio

6.2.5 Galectin Therapeutics Inc (US) Recent Developments/Updates

6.3 G3 Pharmaceuticals (India)

6.3.1 G3 Pharmaceuticals (India) Corporation Information

6.3.2 G3 Pharmaceuticals (India) Description and Business Overview

6.3.3 G3 Pharmaceuticals (India) Galectin Inhibitor Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.3.4 G3 Pharmaceuticals (India) Galectin Inhibitor Therapeutics Product Portfolio

6.3.5 G3 Pharmaceuticals (India) Recent Developments/Updates

6.4 iTeos (US)

6.4.1 iTeos (US) Corporation Information

6.4.2 iTeos (US) Description and Business Overview

6.4.3 iTeos (US) Galectin Inhibitor Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.4.4 iTeos (US) Galectin Inhibitor Therapeutics Product Portfolio

6.4.5 iTeos (US) Recent Developments/Updates

6.5 MandalMed, Inc (US)

6.5.1 MandalMed, Inc (US) Corporation Information

6.5.2 MandalMed, Inc (US) Description and Business Overview

6.5.3 MandalMed, Inc (US) Galectin Inhibitor Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.5.4 MandalMed, Inc (US) Galectin Inhibitor Therapeutics Product Portfolio

6.5.5 MandalMed, Inc (US) Recent Developments/Updates

6.6 Angion (US)

6.6.1 Angion (US) Corporation Information

6.6.2 Angion (US) Description and Business Overview

6.6.3 Angion (US) Galectin Inhibitor Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Angion (US) Galectin Inhibitor Therapeutics Product Portfolio

6.6.5 Angion (US) Recent Developments/Updates

6.7 Novartis AG (Switzerland)

6.6.1 Novartis AG (Switzerland) Corporation Information

6.6.2 Novartis AG (Switzerland) Description and Business Overview

6.6.3 Novartis AG (Switzerland) Galectin Inhibitor Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Novartis AG (Switzerland) Galectin Inhibitor Therapeutics Product Portfolio

6.7.5 Novartis AG (Switzerland) Recent Developments/Updates

6.8 Galecto Biotech (Denmark)

6.8.1 Galecto Biotech (Denmark) Corporation Information

6.8.2 Galecto Biotech (Denmark) Description and Business Overview

6.8.3 Galecto Biotech (Denmark) Galectin Inhibitor Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Galecto Biotech (Denmark) Galectin Inhibitor Therapeutics Product Portfolio

6.8.5 Galecto Biotech (Denmark) Recent Developments/Updates

6.9 Pfizer Inc. (US)

6.9.1 Pfizer Inc. (US) Corporation Information

6.9.2 Pfizer Inc. (US) Description and Business Overview

6.9.3 Pfizer Inc. (US) Galectin Inhibitor Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Pfizer Inc. (US) Galectin Inhibitor Therapeutics Product Portfolio

6.9.5 Pfizer Inc. (US) Recent Developments/Updates

6.10 Lilly (US)

6.10.1 Lilly (US) Corporation Information

6.10.2 Lilly (US) Description and Business Overview

6.10.3 Lilly (US) Galectin Inhibitor Therapeutics Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Lilly (US) Galectin Inhibitor Therapeutics Product Portfolio

6.10.5 Lilly (US) Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Galectin Inhibitor Therapeutics Industry Chain Analysis

7.2 Galectin Inhibitor Therapeutics Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Galectin Inhibitor Therapeutics Production Mode & Process

7.4 Galectin Inhibitor Therapeutics Sales and Marketing

7.4.1 Galectin Inhibitor Therapeutics Sales Channels

7.4.2 Galectin Inhibitor Therapeutics Distributors

7.5 Galectin Inhibitor Therapeutics Customers

8 Galectin Inhibitor Therapeutics Market Dynamics

8.1 Galectin Inhibitor Therapeutics Industry Trends

8.2 Galectin Inhibitor Therapeutics Market Drivers

8.3 Galectin Inhibitor Therapeutics Market Challenges

8.4 Galectin Inhibitor Therapeutics Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

GlycoMimetics (US)

Galectin Therapeutics Inc (US)

iTeos (US)

MandalMed, Inc (US)

Angion (US)

Novartis AG (Switzerland)

Galecto Biotech (Denmark)

Pfizer Inc. (US)

Lilly (US)

List of Tables

Table 1. Global Galectin Inhibitor Therapeutics Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Galectin Inhibitor Therapeutics Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Galectin Inhibitor Therapeutics Market Competitive Situation by Manufacturers in 2023

Table 4. Global Galectin Inhibitor Therapeutics Sales (Kiloton) of Key Manufacturers (2019-2024)

Table 5. Global Galectin Inhibitor Therapeutics Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Galectin Inhibitor Therapeutics Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Galectin Inhibitor Therapeutics Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Galectin Inhibitor Therapeutics Average Price (US$/Ton) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Galectin Inhibitor Therapeutics, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Galectin Inhibitor Therapeutics, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Galectin Inhibitor Therapeutics, Product Type & Application

Table 12. Global Key Manufacturers of Galectin Inhibitor Therapeutics, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Galectin Inhibitor Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Galectin Inhibitor Therapeutics as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Galectin Inhibitor Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Galectin Inhibitor Therapeutics Sales by Region (2019-2024) & (Kiloton)

Table 18. Global Galectin Inhibitor Therapeutics Sales Market Share by Region (2019-2024)

Table 19. Global Galectin Inhibitor Therapeutics Sales by Region (2025-2030) & (Kiloton)

Table 20. Global Galectin Inhibitor Therapeutics Sales Market Share by Region (2025-2030)

Table 21. Global Galectin Inhibitor Therapeutics Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Galectin Inhibitor Therapeutics Revenue Market Share by Region (2019-2024)

Table 23. Global Galectin Inhibitor Therapeutics Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Galectin Inhibitor Therapeutics Revenue Market Share by Region (2025-2030)

Table 25. North America Galectin Inhibitor Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Galectin Inhibitor Therapeutics Sales by Country (2019-2024) & (Kiloton)

Table 27. North America Galectin Inhibitor Therapeutics Sales by Country (2025-2030) & (Kiloton)

Table 28. North America Galectin Inhibitor Therapeutics Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Galectin Inhibitor Therapeutics Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Galectin Inhibitor Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Galectin Inhibitor Therapeutics Sales by Country (2019-2024) & (Kiloton)

Table 32. Europe Galectin Inhibitor Therapeutics Sales by Country (2025-2030) & (Kiloton)

Table 33. Europe Galectin Inhibitor Therapeutics Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Galectin Inhibitor Therapeutics Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Galectin Inhibitor Therapeutics Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Galectin Inhibitor Therapeutics Sales by Region (2019-2024) & (Kiloton)

Table 37. Asia Pacific Galectin Inhibitor Therapeutics Sales by Region (2025-2030) & (Kiloton)

Table 38. Asia Pacific Galectin Inhibitor Therapeutics Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Galectin Inhibitor Therapeutics Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Galectin Inhibitor Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Galectin Inhibitor Therapeutics Sales by Country (2019-2024) & (Kiloton)

Table 42. Latin America Galectin Inhibitor Therapeutics Sales by Country (2025-2030) & (Kiloton)

Table 43. Latin America Galectin Inhibitor Therapeutics Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Galectin Inhibitor Therapeutics Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Galectin Inhibitor Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Galectin Inhibitor Therapeutics Sales by Country (2019-2024) & (Kiloton)

Table 47. Middle East & Africa Galectin Inhibitor Therapeutics Sales by Country (2025-2030) & (Kiloton)

Table 48. Middle East & Africa Galectin Inhibitor Therapeutics Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Galectin Inhibitor Therapeutics Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Galectin Inhibitor Therapeutics Sales (Kiloton) by Type (2019-2024)

Table 51. Global Galectin Inhibitor Therapeutics Sales (Kiloton) by Type (2025-2030)

Table 52. Global Galectin Inhibitor Therapeutics Sales Market Share by Type (2019-2024)

Table 53. Global Galectin Inhibitor Therapeutics Sales Market Share by Type (2025-2030)

Table 54. Global Galectin Inhibitor Therapeutics Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Galectin Inhibitor Therapeutics Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Galectin Inhibitor Therapeutics Revenue Market Share by Type (2019-2024)

Table 57. Global Galectin Inhibitor Therapeutics Revenue Market Share by Type (2025-2030)

Table 58. Global Galectin Inhibitor Therapeutics Price (US$/Ton) by Type (2019-2024)

Table 59. Global Galectin Inhibitor Therapeutics Price (US$/Ton) by Type (2025-2030)

Table 60. Global Galectin Inhibitor Therapeutics Sales (Kiloton) by Application (2019-2024)

Table 61. Global Galectin Inhibitor Therapeutics Sales (Kiloton) by Application (2025-2030)

Table 62. Global Galectin Inhibitor Therapeutics Sales Market Share by Application (2019-2024)

Table 63. Global Galectin Inhibitor Therapeutics Sales Market Share by Application (2025-2030)

Table 64. Global Galectin Inhibitor Therapeutics Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Galectin Inhibitor Therapeutics Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Galectin Inhibitor Therapeutics Revenue Market Share by Application (2019-2024)

Table 67. Global Galectin Inhibitor Therapeutics Revenue Market Share by Application (2025-2030)

Table 68. Global Galectin Inhibitor Therapeutics Price (US$/Ton) by Application (2019-2024)

Table 69. Global Galectin Inhibitor Therapeutics Price (US$/Ton) by Application (2025-2030)

Table 70. GlycoMimetics (US) Corporation Information

Table 71. GlycoMimetics (US) Description and Business Overview

Table 72. GlycoMimetics (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)

Table 73. GlycoMimetics (US) Galectin Inhibitor Therapeutics Product

Table 74. GlycoMimetics (US) Recent Developments/Updates

Table 75. Galectin Therapeutics Inc (US) Corporation Information

Table 76. Galectin Therapeutics Inc (US) Description and Business Overview

Table 77. Galectin Therapeutics Inc (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)

Table 78. Galectin Therapeutics Inc (US) Galectin Inhibitor Therapeutics Product

Table 79. Galectin Therapeutics Inc (US) Recent Developments/Updates

Table 80. G3 Pharmaceuticals (India) Corporation Information

Table 81. G3 Pharmaceuticals (India) Description and Business Overview

Table 82. G3 Pharmaceuticals (India) Galectin Inhibitor Therapeutics Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)

Table 83. G3 Pharmaceuticals (India) Galectin Inhibitor Therapeutics Product

Table 84. G3 Pharmaceuticals (India) Recent Developments/Updates

Table 85. iTeos (US) Corporation Information

Table 86. iTeos (US) Description and Business Overview

Table 87. iTeos (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)

Table 88. iTeos (US) Galectin Inhibitor Therapeutics Product

Table 89. iTeos (US) Recent Developments/Updates

Table 90. MandalMed, Inc (US) Corporation Information

Table 91. MandalMed, Inc (US) Description and Business Overview

Table 92. MandalMed, Inc (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)

Table 93. MandalMed, Inc (US) Galectin Inhibitor Therapeutics Product

Table 94. MandalMed, Inc (US) Recent Developments/Updates

Table 95. Angion (US) Corporation Information

Table 96. Angion (US) Description and Business Overview

Table 97. Angion (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)

Table 98. Angion (US) Galectin Inhibitor Therapeutics Product

Table 99. Angion (US) Recent Developments/Updates

Table 100. Novartis AG (Switzerland) Corporation Information

Table 101. Novartis AG (Switzerland) Description and Business Overview

Table 102. Novartis AG (Switzerland) Galectin Inhibitor Therapeutics Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)

Table 103. Novartis AG (Switzerland) Galectin Inhibitor Therapeutics Product

Table 104. Novartis AG (Switzerland) Recent Developments/Updates

Table 105. Galecto Biotech (Denmark) Corporation Information

Table 106. Galecto Biotech (Denmark) Description and Business Overview

Table 107. Galecto Biotech (Denmark) Galectin Inhibitor Therapeutics Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)

Table 108. Galecto Biotech (Denmark) Galectin Inhibitor Therapeutics Product

Table 109. Galecto Biotech (Denmark) Recent Developments/Updates

Table 110. Pfizer Inc. (US) Corporation Information

Table 111. Pfizer Inc. (US) Description and Business Overview

Table 112. Pfizer Inc. (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)

Table 113. Pfizer Inc. (US) Galectin Inhibitor Therapeutics Product

Table 114. Pfizer Inc. (US) Recent Developments/Updates

Table 115. Lilly (US) Corporation Information

Table 116. Lilly (US) Description and Business Overview

Table 117. Lilly (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)

Table 118. Lilly (US) Galectin Inhibitor Therapeutics Product

Table 119. Lilly (US) Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Galectin Inhibitor Therapeutics Distributors List

Table 123. Galectin Inhibitor Therapeutics Customers List

Table 124. Galectin Inhibitor Therapeutics Market Trends

Table 125. Galectin Inhibitor Therapeutics Market Drivers

Table 126. Galectin Inhibitor Therapeutics Market Challenges

Table 127. Galectin Inhibitor Therapeutics Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Galectin Inhibitor Therapeutics

Figure 2. Global Galectin Inhibitor Therapeutics Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Galectin Inhibitor Therapeutics Market Share by Type in 2023 & 2030

Figure 4. Natural Product Picture

Figure 5. Synthetic Product Picture

Figure 6. Global Galectin Inhibitor Therapeutics Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Galectin Inhibitor Therapeutics Market Share by Application in 2023 & 2030

Figure 8. Diabetes

Figure 9. Heart Failure

Figure 10. Asthma

Figure 11. Rheumatoid Arthritis

Figure 12. Other

Figure 13. Global Galectin Inhibitor Therapeutics Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Galectin Inhibitor Therapeutics Market Size (2019-2030) & (US$ Million)

Figure 15. Global Galectin Inhibitor Therapeutics Sales (2019-2030) & (Kiloton)

Figure 16. Global Galectin Inhibitor Therapeutics Average Price (US$/Ton) & (2019-2030)

Figure 17. Galectin Inhibitor Therapeutics Report Years Considered

Figure 18. Galectin Inhibitor Therapeutics Sales Share by Manufacturers in 2023

Figure 19. Global Galectin Inhibitor Therapeutics Revenue Share by Manufacturers in 2023

Figure 20. The Global 5 and 10 Largest Galectin Inhibitor Therapeutics Players: Market Share by Revenue in 2023

Figure 21. Galectin Inhibitor Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 22. Global Galectin Inhibitor Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 23. North America Galectin Inhibitor Therapeutics Sales Market Share by Country (2019-2030)

Figure 24. North America Galectin Inhibitor Therapeutics Revenue Market Share by Country (2019-2030)

Figure 25. United States Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Canada Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Europe Galectin Inhibitor Therapeutics Sales Market Share by Country (2019-2030)

Figure 28. Europe Galectin Inhibitor Therapeutics Revenue Market Share by Country (2019-2030)

Figure 29. Germany Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. France Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. U.K. Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Italy Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Russia Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Galectin Inhibitor Therapeutics Sales Market Share by Region (2019-2030)

Figure 35. Asia Pacific Galectin Inhibitor Therapeutics Revenue Market Share by Region (2019-2030)

Figure 36. China Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Japan Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. South Korea Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. India Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Australia Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. China Taiwan Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Indonesia Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Thailand Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Malaysia Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Latin America Galectin Inhibitor Therapeutics Sales Market Share by Country (2019-2030)

Figure 46. Latin America Galectin Inhibitor Therapeutics Revenue Market Share by Country (2019-2030)

Figure 47. Mexico Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Brazil Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Argentina Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Middle East & Africa Galectin Inhibitor Therapeutics Sales Market Share by Country (2019-2030)

Figure 51. Middle East & Africa Galectin Inhibitor Therapeutics Revenue Market Share by Country (2019-2030)

Figure 52. Turkey Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Saudi Arabia Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. UAE Galectin Inhibitor Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. Global Sales Market Share of Galectin Inhibitor Therapeutics by Type (2019-2030)

Figure 56. Global Revenue Market Share of Galectin Inhibitor Therapeutics by Type (2019-2030)

Figure 57. Global Galectin Inhibitor Therapeutics Price (US$/Ton) by Type (2019-2030)

Figure 58. Global Sales Market Share of Galectin Inhibitor Therapeutics by Application (2019-2030)

Figure 59. Global Revenue Market Share of Galectin Inhibitor Therapeutics by Application (2019-2030)

Figure 60. Global Galectin Inhibitor Therapeutics Price (US$/Ton) by Application (2019-2030)

Figure 61. Galectin Inhibitor Therapeutics Value Chain

Figure 62. Galectin Inhibitor Therapeutics Production Process

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Distributors Profiles

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Genome Engineering Editing Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-34Q14901

Fri Oct 04 00:00:00 UTC 2024

Add to Cart

Global Nasal Administration Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-12L16880

Fri Oct 04 00:00:00 UTC 2024

Add to Cart

Global Pharmaceutical Ggrade Probiotics Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-32O11372

Fri Oct 04 00:00:00 UTC 2024

Add to Cart

Global Rapid Diagnostic Reagent Filler Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-38K13957

Fri Oct 04 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions